Company / Free Cash Flow
NovoCure Ltd Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$75.7M
FY2025
5-year range
-$100.4M / $84.2M
FY2021-FY2025
Trend
-9.3%
vs FY2024
Sector context
#139 of 151
Health Care
What the data says
Among 151 Health Care companies, NovoCure Ltd is in the bottom 8% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from -$113M in FY2018 to $84M in FY2022.
Based on SEC 10-K filings.
-$76M in FY2025.
Improved from -$100M to -$76M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 151This company -$75.7M Sector average $779.8M
▼
-109.7% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 9.3% year-over-year.
- Ranks #139 out of 151 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2022.
- Lowest free cash flow in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$75.7M | -9.3% |
| FY2024 | -$69.2M | +31.1% |
| FY2023 | -$100.4M | -219.3% |
| FY2022 | $84.2M | +421.7% |
| FY2021 | $16.1M | +288.1% |
| FY2020 | -$8.6M | +78.8% |
| FY2019 | -$40.5M | +64.2% |
| FY2018 | -$113.3M | -8.3% |
| FY2017 | -$104.6M | -39.2% |
| FY2016 | -$75.1M | -36.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026